Sanofi
2 years ago ⋅ English ⋅ 5 min read
Newsroom
Media Update: Sanofi presents new data from robust MS clinical pipeline exploring multiple approaches to address important unmet patient needs

Sanofi presents new data from robust MS clinical pipeline exploring multiple approaches to address important unmet patient needsParis, October 2, 2023. Sanofi will present new data at t... Read More
Sanofi
2 years ago ⋅ English ⋅ 3 min read
Newsroom
Media Update: Sanofi completes acquisition of Qunol®

Sanofi completes acquisition of Qunol®Paris, September 29, 2023. Sanofi announced today the completion of its acquisition of Qunol, a U.S.-based market leading brand in health &... Read More
Sanofi
2 years ago ⋅ English ⋅ 10 min read
Newsroom
Dupixent® (dupilumab) sBLA for treatment of eosinophilic esophagitis in children aged 1 to 11 accepted for FDA Priority Review

Dupixent® (dupilumab) sBLA for treatment of eosinophilic esophagitis in children aged 1 to 11 accepted for FDA Priority Review- If approved, Dupixent would be the first and only tre... Read More
Sanofi
2 years ago ⋅ English ⋅ 6 min read
Newsroom
Once-weekly ALTUVIIIO® approved in Japan as a new class of factor VIII therapy for hemophilia A

Once-weekly ALTUVIIIO® approved in Japan as a new class of factor VIII therapy for hemophilia A- ALTUVIIIO is a first-in-class, high-sustained factor VIII replacement therapy which... Read More
Sanofi
2 years ago ⋅ English ⋅ 2 min read
Newsroom
Availability of the Q3 2023 Memorandum for modelling purposes

Availability of the Q3 2023 Memorandum for modelling purposesParis, France – September 22, 2023. Sanofi announced today that its Q3 2023 Memorandum for modelling purposes is avail... Read More
Sanofi
2 years ago ⋅ English ⋅ 7 min read
Newsroom
Sanofi supporting vulnerable communities as part of commitment to social impact and fight against climate change

Sanofi supporting vulnerable communities as part of commitment to social impact and fight against climate changeParis, September 19, 2023 – As global leaders gather at the United... Read More